short term trading

Galena Biopharma, Inc. (NASDAQ: GALE) saw its shares jump on Wednesday after a key U.S. Food and Drug Administration (FDA) approval. The company announced that it has confirmed the regulatory pathway to advance GALE-401 (Anagrelide Controlled Release) into a pivotal, Phase 3 trial.

After a productive meeting with the FDA, Galena has confirmed the development program and proposed clinical trial are appropriate for a New Drug Application (NDA) filing.

The Phase 3 clinical trial will enroll patients with essential thrombocythemia who have either failed or are intolerant to hydroxyurea, and will compare GALE-401 to the best available therapy (BAT) that will include a sizable subpopulation of patients treated with anagrelide immediate release.

Galena expects to finalize the Phase 3 clinical trial protocol and initiate the trial in the second quarter of 2017.

Mark W. Schwartz, Ph.D., President and CEO of Galena, commented:

Confirmation of the 505(b)(2) regulatory pathway and preliminary agreement with the Agency on our Phase 3 clinical trial design is a significant step forward for our late stage program. Our controlled release version of anagrelide can offer a potential treatment option for patients with ET who have failed hydroxyurea. We remain on track to initiate the trial in the second quarter of 2017.

short term trading: Stage Stores, Inc.(SSI)

Advisors’ Opinion:

  • [By Paul Ausick]

    Stage Stores Inc. (NYSE: SSI) dropped nearly 20% on Monday to post a new 52-week low of $3.21 after closing at $4.00 on Friday. Volume was more than 5 times the daily average of about 650,000 shares. The company posted poor holiday season sales last Friday and lowered its guidance.

  • [By Lisa Levin]

    Stage Stores Inc (NYSE: SSI) was down, falling around 16 percent to $3.35 as the company reported a drop in its holiday season same-store sales and lowered its earnings guidance. The retailer’s same-store sales dropped 7.3 percent for the nine-week period ending December 31, 2016.

short term trading: Innoviva, Inc. (INVA)

Advisors’ Opinion:

  • [By Sean Williams]

    Shares of Innoviva (NASDAQ:INVA), a biotechnology royalty company that develops respiratory therapeutics and is perhaps best known as GlaxoSmithKline’s (NYSE:GSK) development partner for its multiple next-generation COPD and asthma products, fell as much as 11% on Thursday. The reason behind Innoviva’s bad day can be traced to a proxy battle with activist hedge fund Sarissa Capital Management over seats on its board.

short term trading: Las Vegas Sands Corp.(LVS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Wynn wasn’t the only Macau casino operator that took it on the chin today. Las Vegas Sands (LVS) tumbled 13% to $54.67, while Melco Crown Entertainment (MPEL) plunged 14% to $16.87, and MGM Resorts International (MGM) dropped 4.3% to $28.65.

  • [By WWW.THESTREET.COM]

    Cramer recalled how, in 2009, colleague Dan Fitzpatrick correctly identified Las Vegas Sands (LVS) as it broke out of its $10 a share funk and soared to $48, almost in a straight line. This technical move was brought on by Sands’ red-hot properties in Macau.

  • [By Wayne Duggan]

    The firm has a Market-Perform rating on the China unit of Las Vegas Sands Corp. (NYSE: LVS).

    All four stocks are up between 3.8 and 11.2 percent in the past month.

short term trading: Coupa Software Incorporated (COUP)

Advisors’ Opinion:

  • [By Taylor Cox]

    Analyst/Investor Days

    Coupa Software Incorporated (NASDAQ: COUP)
    Equifax Inc (NYSE: EFX) in New York

    Annual Shareholder Meetings

    1-800-Flowers.com, Inc (NASDAQ: FLWS)
    Cicso Systems, Inc (NASDAQ: CSCO)

    Tuesday

Leave a Reply

Your email address will not be published. Required fields are marked *